16/05/2024  16:48:02 Diferencia - Volumen Bid9:03:47 Ask17:30:00 Capitalización de mecado Dividendo A. P/E Ratio
37.00EUR - 85
Volumen de negocios: 3,145
-Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 1.66 mil millonesEUR 2.85% 26.59

Descripción de negocio

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand.
 

Consejo de gestión & Consejo de supervisión

CEO
Dr. Hans-Georg Feldmeier
Consejo de gestión
Dr. Andreas Eberhorn, Christof Dreibholz
Consejo de supervisión
Wilhelm Beier, Dr. Erwin Kern, Lothar Lanz
 

Datos de la empresa

Nombre: Dermapharm Holding SE
Dirección: Lil-Dagover-Ring 7,D-82031 Grünwald
Teléfono: +49-89-64186-0
Fax: +49-89-64186-130
E-mail: -
Internet: ir.dermapharm.de/index.php
Industria: Healthcare
Sector: Pharmaceutical Industry
Subsector: Pharmaceuticals
Fin del año financiero: 31/12
Acciones de libre circulación: -
Fecha de OPI: 09/02/2018

Relación con inversores

Nombre: Britta Hamberger
IR teléfono: +49-89-64186-233
IR-fax: +49-89-64186-165
IR e-mail: ir@dermapharm.com

Calendario de la empresa

CW 46 | 14/11/2024 Interim Report 3rd Quarter/9 Months
 

Accionistas mayoritarios

Themis Beteiligungs-AG
 
68.50%
FreeFloat
 
31.50%